Jacobio Pharmaceuticals Secures 80% Equity Investment in Jacoray from Oceanpine Capital
Jacobio Pharmaceuticals (HKG: 1167) today announced a capital‑increase and equity‑transfer agreement that will see Shanxi...
HELP Therapeutics Secures NMPA Approval for HiCM388, China’s First Cell‑Based Therapy for STEMI
HELP Therapeutics Corp., a pioneer in cell‑based therapeutics, announced that the National Medical Products Administration...
Abbott Reports Q3 2025 Revenue of $11.369 B, Up 6.9% YoY – Strong Growth Across Nutrition & Devices Segments
Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September 30, 2025. For...
Haihe Biopharma Grants Taiho Pharmaceutical Exclusive License for Risovalisib in Japan
China‑based Haihe Biopharma Co., Ltd. (the “Licensor”) announced today that it has entered into an...
Genesis Healthcare & MGI Sign Strategic MOU to Accelerate Precision Medicine in Japan
Genesis Healthcare, a leading Japanese genetic‑testing provider, today announced the signing of a Memorandum of...
Nuance Pharma Partners with Stallergenes Greer to Launch Actair in China
Nuance Pharma, an innovation-focused biopharmaceutical company, and Stallergenes Greer, a global leader in the allergy...
Pfizer CEO Bourla Highlights Benefits of China Biotech Collaborations at NY Gala
Albert Bourla, CEO of Pfizer Inc. (NYSE: PFE), highlighted the benefits of collaborations between multinational...
Uni-Bio Science Partners with Sinovac to Expand Teriparatide Injection Globally
Uni-Bio Science Group Limited (HKG: 0690), a China-based company, announced on September 12, 2025, that...
Adagene Expands Exelixis Collaboration to Include Third Target Using SAFEbody Technology
Adagene Inc. (NASDAQ: ADAG) announced on September 16, 2025, that its collaboration and license agreement...
Ollin Biosciences Launches With $100M Funding to Advance Ophthalmology Pipeline
Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company, announced its launch on September 16, 2025,...
China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into...
Livzon Launches China’s First Oral GnRH Antagonist for Multiple Indications
Livzon Pharmaceutical Group Inc. (HKG: 1513), a China-based company, announced on September 10, 2025, the...
Pacific Shuanglin’s Controlling Stake Transferred to CNBG in RMB 4.7B Deal
Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE: 000403), a China-based blood products company, announced that its...
Jingze Bio and CMS Subsidiary Partner to Commercialize Key Products in Reproduction and Ophthalmology
On September 12, 2025, Jingze Biopharmaceutical (Hefei) Co., Ltd., based in China, and a subsidiary...
Sino Biopharmaceutical’s Partner CTTQ Secures Breakthrough Therapy Designation for TQ‑B3234 Capsule in China
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of China‑based Sino Biopharmaceutical Ltd. (HKG: 1177), today...
Pfizer Reports Positive Phase 3 HER2CLIMB‑05 Results for TUKYSA (Tucatinib) in First‑Line HER2+ MBC
Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase 3 HER2CLIMB‑05 trial, evaluating...
Zennova & Rapafusyn Forge Alliance to Accelerate Non‑Degrading Molecular Glue Therapies
Zennova Pharmaceutical announced today a strategic partnership with U.S.‑based biotech Rapafusyn Pharmaceuticals to jointly develop...